People who are at an increased risk of thrombosis (clots) are often given antiplatelet drugs such as clopidogrel and prasugrel. These drugs work by reducing the activity of platelets, thereby reducing the risk of clots forming. It is understood that obese and diabetic people have more reactive platelets than healthy people. These subgroups of people therefore have an increased risk of having a heart attack or a stroke, even if they are taking these antiplatelet drugs. The processes that lead to this increased platelet reactivity in obese and patients with diabetes are unclear. This project aims to determine whether there is an association between BMI/insulin and increased platelet reactivity in young adults and to identify potential causes of this increased reactivity.